The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

In the province of West Sumatra, Indonesia, in the early hours of Monday, March 9, 2026, Mount Marapi registered a powerful eruption. Major update in search for missing Gus One type of drinking water ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

Geroscience examines the underlying biology of aging to delay chronic diseases and extend the healthy years of human life.

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

In veterans with type 2 diabetes, treatment with GLP-1 receptor agonists was associated with a reduced risk for various substance use disorders compared with sodium-glucose cotransporter-2, or SGLT-2, ...

Therapies backed only by lower-tier evidence no better than unmatched treatment ...